| Recruiting | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorecta Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia | Phase 2 | 2025-06-25 |
| Withdrawn | A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects Wi Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | 2024-10-21 |
| Withdrawn | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies CRC | Phase 2 | 2023-11-14 |
| Unknown | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Pancreatic Cancer, Breast Cancer, Gastric Cancer | Phase 1 | 2022-05-11 |
| Active Not Recruiting | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced o Pancreatic Cancer, Breast Cancer, Gastric Cancer | Phase 1 | 2022-03-31 |
| Active Not Recruiting | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Mal Mesothelioma, Glioblastoma, Renal Cell Carcinoma | Phase 1 / Phase 2 | 2021-06-09 |
| Completed | Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects Healthy Male | Phase 1 | 2021-04-13 |
| Completed | Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function Impaired Hepatic Function | Phase 1 | 2021-04-01 |
| Terminated | A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and t SARS-CoV-2 Infection | Phase 1 / Phase 2 | 2020-11-09 |
| Completed | A Study of NGM621 in Participants With Geographic Atrophy Geographic Atrophy | Phase 2 | 2020-07-22 |
| Completed | Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) Compensated Cirrhosis, Nonalcoholic Steatohepatitis | Phase 2 | 2020-03-23 |
| Completed | Study of NGM395 in Adult Participants Obesity, NAFLD | Phase 1 | 2020-02-13 |
| Completed | Study of Aldafermin (NGM282) in Participants With Impaired Renal Function Impaired Renal Function | Phase 1 | 2019-11-08 |
| Completed | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combinati Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer | Phase 1 / Phase 2 | 2019-10-16 |
| Completed | Study of NGM621 in Participants With Geographic Atrophy Geographic Atrophy | Phase 1 | 2019-07-26 |
| Completed | Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo NASH - Nonalcoholic Steatohepatitis | Phase 2 | 2019-05-16 |
| Completed | Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects Cachexia | Phase 1 | 2018-01-29 |
| Completed | Study of NGM313 in Obese Participants Obese | Phase 1 | 2017-09-11 |
| Completed | A Study of NGM282 in Patients With Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis | Phase 2 | 2016-03-01 |
| Completed | Phase 1 Study of NGM313 in Healthy Adult Participants Obesity | Phase 1 | 2016-02-01 |
| Completed | Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals Functional Constipation | Phase 1 / Phase 2 | 2015-12-01 |
| Completed | Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) Nonalcoholic Steatohepatitis (NASH) | Phase 2 | 2015-07-31 |
| Completed | Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis Primary Biliary Cirrhosis | Phase 2 | 2014-05-01 |
| Completed | Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis Primary Biliary Cirrhosis | Phase 2 | 2014-02-01 |
| Completed | Phase 2 Study of NGM282 in Patients With Type 2 Diabetes Diabetes Mellitus | Phase 2 | 2013-09-01 |
| Completed | Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants Diabetes Mellitus | Phase 1 | 2013-01-01 |